Medindia LOGIN REGISTER
Medindia
Advertisement

Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts

Wednesday, November 12, 2008 General News
Advertisement
MOUNTAIN VIEW, Calif., Nov. 11 AlexzaPharmaceuticals, Inc. (Nasdaq: ALXA) today announced that company Presidentand CEO Thomas B. King will present at the following investor conferences inNovember and December:
Advertisement

A live webcast of each presentation can be accessed via the InvestorRelations section of the Alexza website, at http://www.alexza.com. A replayof each webcast will be available on the website approximately 24 hours afterthe live presentation and will be archived for 14 days.
Advertisement

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging specialty pharmaceutical companyfocused on the development and commercialization of novel, proprietaryproducts for the treatment of acute and intermittent conditions. TheCompany's technology, the Staccato(R) system, vaporizes unformulated drug toform a condensation aerosol that allows rapid systemic drug delivery throughdeep lung inhalation. The drug is quickly absorbed through the lungs into thebloodstream, providing speed of therapeutic onset that is comparable tointravenous administration, but with greater ease, patient comfort andconvenience.

Alexza has five product candidates in clinical development. Alexza's leadprogram, AZ-004 (Staccato loxapine) for the treatment of acute agitation inschizophrenic or bipolar disorder patients, has completed one Phase 3 clinicaltrial and enrolled a second Phase 3 trial. The Company has completed itsend-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine),which is intended for the acute treatment of migraine headache, and it hasadvanced AZ-104 (Staccato loxapine) to Phase 2 testing. Product candidatesthat have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for thetreatment of breakthrough pain, which is partnered with Endo Pharmaceuticalsin North America, and AZ-007 (Staccato zaleplon) for the treatment ofinsomnia. In addition, AZ-002 (Staccato alprazolam) has completed a Phase 2aproof-of-concept clinical trial for the treatment of panic attacks -- anindication the Company is not planning to pursue -- and is being assessed forother possible indications and renewed clinical development. Moreinformation, including this and past press releases from Alexza, is availableonline at http://www.alexza.com.

Safe Harbor Statement

The anticipated presentations will contain forward-looking statements thatinvolve significant risks and uncertainties. Any statement describing theCompany's expectations or beliefs is a forward-looking statement, as definedin the Private Securities Litigation Reform Act of 1995, and should beconsidered an at-risk statement. Such statements are subject to certain risksand uncertainties, particularly those inherent in the process of developingand commercializing drugs. The Company's forward-looking statements alsoinvolve assumptions that, if they prove incorrect, would cause its results todiffer materially from those expressed or implied by such forward-lookingstatements. These and other risks concerning Alexza's business are describedin additional detail in the Company's Annual Report on Form 10-K for the yearended December 31, 2007, and the Company's other Periodic and Current Reportsfiled with the Securities and Exchange Commission. Forward-looking statementscontained in this announcement are made as of this date, and the Companyundertakes no obligation to publicly update any forward-looking statement,whether as a result of new information, future events or otherwise.Lazard Capital Markets 5th Annual Healthcare Conference The St. Regis Hotel 2 East 55th Street, New York Presentation: Tuesday, November 18, 2008 at 5:10 p.m. ET 20th Annual Piper Jaffray Health Care Conference The New York Palace Hotel 455 Madison Avenue, New York Presentation: Tuesday, December 2, 2008 at 9:30 a.m. ET RBC Capital Markets 2008 Healthcare Conference The Westin Times Square Hotel 270 West 43rd Street, New York Presentation: Wednesday, December 10, 2008 at 8:00 a.m. ET

SOURCE Alexza Pharmaceuticals, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close